Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Derek Cogan

Ming-Hong Hao

Zhaoming Xiong

Matthew Russell Netherton

Craig Andrew Miller

Daniel R Goldberg

Alan David Swinamer

Zhidong Chen

Donghong Amy Gao

Daniel Richard Marshall

Alexander Heim-Riether

Bryan Patrick McKibben

Ronald A Aungst, Jr

Jennifer Burke

Philip Dean Ramsden

Neil Moss

Yunlong Zhang

John Lord

Michael Balestra

Xin Guo

Kenneth Michael Meyers

Roger John Snow

Lana Louise Smith Keenan

Lee Fader

Maolin Yu

Victor Marc Kamhi

Kevin Chungeng Qian

Hui Yu

Yang Yu

Amy L Davis

Eugene R Hickey

Weimin Liu

Denice Mary Spero

Mario G Cardozo

Rene Marc Lemieux

Christopher Ronald Sarko

Erick Richard Roush Young

Abdelhakim Hammach

Charles Lawrence Cywin

Zhonghua Zhang

Keith R Hornberger

Heather Tye

Mark Whittaker

Michael Jason Burke

Peter Allen Nemoto

Pui Leng Loke

John David Ginn

Jiang-Ping Wu

Steven Richard Brunette

Asitha Abeywardane

Matt Aaron Tschantz

Wang Mao

Darren DiSalvo

Joerg Bentzien

Jennifer A Kowalski

Jörg Martin Bentzien

Joshua Courtney Horan

Michael David Lawlor

David Charles Thompson

Simon Suprenant

Antonio Jose Del Moral Barbosa, Jr

Yu Yang

Anthony S Prokopowicz, Iii

George Dahmann

Younggi Choi

Samantha Jayne Bamford

Matthew A Cerny

Kosea S Frederick

Criag Andrew Miller

Antonio Jose Del Moral Barbosa

Donghong A Gao

Bryan Mckibben

Joerg Martin Bentzien

Kenneth M Meyers

Jörg Bentzien

Simon Surprenant

Bryan P Mckibben

Ronald A Aungst

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Aldosterone synthase inhibitors

The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R-R, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed is a compound of formula (I). Wherein R, RAr and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10. 

[object Object]

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same. 

Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds. 

Serotonin 5-HT2B receptor inhibitors

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The application relates to compounds of formula Ia and analogues thereof wherein Rto Rand X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are compounds of formula (I)  Where Ar, X, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Anti-cytokine heterocyclic compounds

Growing community of inventors

Sandy Hook, CT, United States of America

Derek Cogan